(Reuters) – Moderna Inc. said on Monday it had administered the first patients in an early-stage study of a new COVID-19 vaccine candidate to assess its potential as a booster.
The company said its new candidate, mRNA-1283, could be stored in refrigerators instead of freezers, facilitating its distribution, especially in developing countries.
The early-stage study will evaluate the safety and immunogenicity of mRNA-1283 at three dose levels and will be given to healthy adults either as a single dose or in two doses, 28 days apart, the company said.
Last week, Moderna began dosing the first participants in a test study of its COVID-19 booster vaccine candidates.
Report by Manojna Maddipatla and Vishwadha Chander in Bengaluru; Editing by Shailesh Kuber and Anil D’Silva